Evidence map›Paper›PMID 39147803›Full record

ArticleScientific reports2024

Prediction of non-muscle invasive bladder cancer recurrence using deep learning of pathology image.

Guang-Yue Wang, Jing-Fei Zhu, Qi-Chao Wang, Jia-Xin Qin, Xin-Lei Wang, Xing Liu, Xin-Yu Liu, Jun-Zhi Chen, Jie-Fei Zhu, Shi-Chao Zhuo and 8 more

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Guang-Yue Wang *Department of Urology, Xuzhou Cancer Hospital, Affiliated Hospital of Jiangsu University, Xuzhou, China.
Jing-Fei Zhu *School of Mathematics and Statistics and Jiangsu Key Laboratory of Education Big Data Science and Engineering, Jiangsu Normal University, No.101, Shanghai Road, Tangshan New District, Xuzhou, Jiangsu, China.
Qi-Chao Wang *Department of Urology, Xuzhou Cancer Hospital, Affiliated Hospital of Jiangsu University, Xuzhou, China.
Jia-Xin QinDepartment of Urology, Xuzhou Central Hospital, Jiefang South Road, No. 199, Xuzhou, Jiangsu, China.
Xin-Lei WangDepartment of Urology, Xuzhou Central Hospital, Jiefang South Road, No. 199, Xuzhou, Jiangsu, China.
Xing LiuDepartment of Urology, Xuzhou Central Hospital, Jiefang South Road, No. 199, Xuzhou, Jiangsu, China.
Xin-Yu LiuDepartment of Urology, Xuzhou Central Hospital, Jiefang South Road, No. 199, Xuzhou, Jiangsu, China.
Jun-Zhi ChenDepartment of Urology, Xuzhou Central Hospital, Jiefang South Road, No. 199, Xuzhou, Jiangsu, China.
Jie-Fei ZhuDepartment of Pathology, Xuzhou Central Hospital, Xuzhou, China.
Shi-Chao ZhuoDepartment of Pathology, Xuzhou Central Hospital, Xuzhou, China.
Di WuDepartment of Pathology, Xuzhou Central Hospital, Xuzhou, China.
Na LiThe First Affiliated Hospital of Kunming Medical University, Kunming, China.
Liu ChaoSchool of Life Sciences, Jiangsu Normal University, Xuzhou, China.
Fan-Lai MengDepartment of Pathology, The Suqian Affiliated Hospital of Xuzhou Medical University, Suqian, China.
Hao LuDepartment of Urology, Heilongjiang Provincial Hospital, Harbin, China.
Zhen-Duo ShiDepartment of Urology, Xuzhou Central Hospital, Jiefang South Road, No. 199, Xuzhou, Jiangsu, China.
Zhi-Gang JiaSchool of Mathematics and Statistics and Jiangsu Key Laboratory of Education Big Data Science and Engineering, Jiangsu Normal University, No.101, Shanghai Road, Tangshan New District, Xuzhou, Jiangsu, China. zhgjia@jsnu.edu.cn.
Cong-Hui HanDepartment of Urology, Xuzhou Central Hospital, Jiefang South Road, No. 199, Xuzhou, Jiangsu, China. hanconghuidoctor@vip.qq.com.

Funding

2023 Xuzhou City to promote science and technology innovation special fund key projects KC232312023 Xuzhou City to promote science and technology innovation special fund key projects KC23233the Jiangsu Province Key Research and Development Program BE2019637the Jiangsu Province Key Research and Development Program BE2020758the Key Projects of Xuzhou Science and Technology Plan KC19075the National Natural Science Foundation of China 12271467the Xuzhou Clinical Medicine Expert Team Project 2018TD004the Xuzhou Medical Key Talents Project XWRCHT20220055the Xuzhou Medical Outstanding Talents Xuzhou Health Education Research [2017] No.22Xuzhou City health Commission general project XWKYHT20220092
6 · The paper itself

Abstract

We aimed to build a deep learning-based pathomics model to predict the early recurrence of non-muscle-infiltrating bladder cancer (NMIBC) in this work. A total of 147 patients from Xuzhou Central Hospital were enrolled as the training cohort, and 63 patients from Suqian Affiliated Hospital of Xuzhou Medical University were enrolled as the test cohort. Based on two consecutive phases of patch level prediction and WSI-level predictione, we built a pathomics model, with the initial model developed in the training cohort and subjected to transfer learning, and then the test cohort was validated for generalization. The features extracted from the visualization model were used for model interpretation. After migration learning, the area under the receiver operating characteristic curve for the deep learning-based pathomics model in the test cohort was 0.860 (95% CI 0.752-0.969), with good agreement between the migration training cohort and the test cohort in predicting recurrence, and the predicted values matched well with the observed values, with p values of 0.667766 and 0.140233 for the Hosmer-Lemeshow test, respectively. The good clinical application was observed using a decision curve analysis method. We developed a deep learning-based pathomics model showed promising performance in predicting recurrence within one year in NMIBC patients. Including 10 state prediction NMIBC recurrence group pathology features be visualized, which may be used to facilitate personalized management of NMIBC patients to avoid ineffective or unnecessary treatment for the benefit of patients.

Indexed as

Deep LearningNeoplasm Recurrence, LocalNon-Muscle Invasive Bladder NeoplasmsAgedFemaleHumansMaleMiddle AgedRisk AssessmentROC Curve

Identifiers

PMID39147803
PMCPMC11327297

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.